Member Info for Laura2022

Diagnostics are way forward

Nice buy

100% up since the previous BOD rushed placing attempt( 0.3p) and now at 9mth highs

New BOD adding much needed momentum

Now 8.5p on the ask

Delayed buys ?

8 13p

Unless a delayed one

Jvip etc

pharma GENI and IMM on the move

FDA/licensing deal

Best wishes here and well done

Moving

How the 3 who claimed to hold and popped up 7 weeks ago have simply vanished:)

0.65 3,248,238

Unlike in previous times

Mgmt and TR1 holder 20-25%

Very re assuring and menas less free float

Moving up

GENI to follow NCYT imho

Not much left 1.15p

Delayed buys as expected jvip

You really are a very strange ill informed individual

Maybe go and spend your time on your investments if you actually have any

Green bin

$1.3 trillion market

O/topic smkrs

IMM also due large licensing deal, currently can buy 50% cheaper than recent 6p placing

ImmuPharma PLC has confirmed that a number of parties have signed Confidential Disclosure Agreements (CDAs/NDAs) as part of the ongoing partnering discussions for their P140 autoimmune platform.

Ongoing Discussions: The company is actively working with potential partners in discussions that are described as "detailed and time-consuming," covering scientific, technical, and commercial aspects of P140.Negotiation Strategy: CEO Tim McCarthy has emphasized a focus on securing a high-value partnership deal over acting quickly, with the aim of achieving the best outcome for shareholders.Progress: Recent positive results from a new study have increased the robustness of the dataset for the P140 programme, which is being used in these discussions.

NT to buy 0.6p

Think they'll be a delayed buy

KEN now at 4 8p

Over 1500% up

Hopefully similar here

Smkrs

Good morning

Full ask or premiums/NT

GENinCode is a genetics company focussed on the prevention of cardiovascular disease ("CVD") and the early detection of ovarian cancer. Significant investment has been made in technology and product development to advance the Company's mission of improving patient outcomes through predictive and preventive care. The Company has recently announced it is working with its partner, Thermo Fisher Scentific, to support its revenue scale-up and expansion strategy .

CVD is the leading cause of death worldwide, responsible for over 17.9 million deaths annually, which equates to approximately 31% of all global deaths (World Health Organisation). With the global annual cost of CVD projected to surpass $1.04 trillion by 2030

First Equity increased their stake in May 2025

New 9% holder in March

Over 60% of market capitalisation in cash

At least 3 funds have increased

Director have bought

Fda clearance due soon

Addressable Market of $1 trillion

Someone else wanted an EXTRA £550,000 shares via extra share subscription in Q1 2026

Cheap stock went and overhang gone

Major contracts and growth due as per presentation